 The primary endpoint will be Progression Free Survival measured from the first treatment in this study until progression. Additional endpoints will be Pharmacokinetics of systemic Irinotecan and SN-38 Irinotecan Bead treatment for feasibility group only; Tumor Response measured according to RECIST; Local tumor response extent of necrosis in the treated lesions; hepatic progression free survival measured from first treatment until progression in the liver; change in tumor markers CEA and optional CA19-9; performance status and overall survival assessed by telephone follow-up. Safety will be measured by assessing Adverse Events and Toxicity according to the NCI CTCAE v3.0 criteria. 